[血液疗法中的病毒安全性。血浆成分疗法中丙型肝炎和细小病毒B19检测的当前情况]
[Viral safety in hemotherapy. Current aspects of hepatitis C and parvovirus B19 detection for plasma component therapy].
作者信息
Sibrowski W, Kühnl P
机构信息
Abt. f. Transfusionsmedizin u. Transplantationsimmunologie, Universitäts-Krankenhaus Eppendorf, Hamburg.
出版信息
Beitr Infusionsther. 1990;26:22-6.
PMID:1703836
Abstract
A major risk of plasma component therapy was the transmission of infectious diseases. Heat inactivation, TNBP/detergent- or beta-propiolactone/UV-treatment were introduced to reduce the risk of virus transmission, most notably those that cause hepatitis or AIDS. Therefore we discuss topical problems of virus inactivation, particularly for the recently discovered hepatitis C-virus and the well-known parvovirus B19.
摘要
血浆成分疗法的一个主要风险是传染病的传播。引入热灭活、TNBP/去污剂或β-丙内酯/紫外线处理以降低病毒传播风险，尤其是那些导致肝炎或艾滋病的病毒。因此，我们讨论病毒灭活的局部问题，特别是针对最近发现的丙型肝炎病毒和著名的细小病毒B19。
Zotero 插件